This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| glucose-6-phosphate dehydrogenase deficiency | |
|---|---|
| Name | Glucose-6-phosphate dehydrogenase deficiency |
| Synonyms | G6PD deficiency |
| Field | Hematology, Genetics |
| Symptoms | Jaundice, hemolytic anemia |
| Complications | Acute hemolytic crisis, neonatal hyperbilirubinemia |
| Onset | Variable |
| Duration | Chronic, episodic |
| Causes | Mutations in G6PD gene |
| Diagnosis | Enzyme assay, genetic testing |
| Treatment | Avoidance of triggers, supportive care, transfusion |
glucose-6-phosphate dehydrogenase deficiency is an X-linked genetic disorder affecting red blood cell metabolism that predisposes individuals to episodic hemolysis. It results from variants in the G6PD gene that impair the pentose phosphate pathway and reduce cellular antioxidant capacity, leading to vulnerability under oxidative stress. Clinical consequences range from asymptomatic laboratory abnormalities to life-threatening neonatal jaundice and acute hemolytic anemia requiring transfusion.
Glucose-6-phosphate dehydrogenase deficiency involves dysfunction of an enzyme central to the pentose phosphate pathway and cellular redox balance, described in relation to syndromes of hemolysis in neonates and adults. Early observations linked hemolytic episodes to exposure to substances or infections, prompting genetic and biochemical investigations by clinicians and laboratories. The disorder is relevant to several populations and has intersections with screening programs, transfusion services, and pharmacogenetic policies in many countries.
The condition is caused by pathogenic variants in the G6PD gene located on the X chromosome, with hemizygous males and heterozygous females showing variable phenotypes influenced by X-chromosome inactivation. Molecular studies characterize numerous missense mutations and polymorphisms that alter enzyme stability, activity, and interaction with NADP+, identified by geneticists and molecular biologists. The lesion impairs production of NADPH in erythrocytes, compromising glutathione recycling and protection from reactive oxygen species generated during infections or drug exposure. Structural and functional analyses by research groups using crystallography and enzymology have elucidated mechanisms by which variant alleles affect protein folding and oligomerization.
Patients may present with acute hemolytic anemia after exposure to oxidative drugs, foods, or infections, manifesting with fatigue, pallor, jaundice, and dark urine; severe cases require hospitalization and transfusion support. Neonatal hyperbilirubinemia can cause kernicterus if untreated, prompting collaboration among pediatricians, neonatologists, and perinatal public health programs. Chronic nonspherocytic hemolytic anemia is rarer and linked to specific unstable variants. Complications include gallstones, splenomegaly, and secondary iron overload in transfusion-dependent individuals, necessitating involvement of hepatologists, hematologists, and transfusion medicine specialists.
Diagnosis combines clinical history, enzyme activity assays, and genetic testing performed in clinical laboratories affiliated with hospitals and academic centers. Screening programs implemented by public health agencies and newborn screening networks use biochemical tests to detect low G6PD activity, with confirmatory molecular testing guided by genetics services. Diagnostic challenges include false-normal enzyme results during hemolysis or in heterozygous females due to lyonization, requiring repeat testing or DNA analysis. Laboratory quality assurance and guidelines from professional societies inform testing algorithms and reporting.
Management centers on prevention by identifying and avoiding known oxidative triggers, informed by pharmacovigilance agencies, drug formularies, and patient education initiatives. Acute hemolytic episodes are treated with supportive care including fluid management, oxygen, transfusion when indicated, and treatment of underlying infections using antimicrobial stewardship principles. Neonatal hyperbilirubinemia is managed with phototherapy and exchange transfusion per neonatal care guidelines; follow-up involves pediatric and neurology services when severe jaundice occurs. Research into antioxidant therapies, enzyme replacement, and gene therapy involves collaborations between academic centers, biotechnology firms, and clinical trial networks.
G6PD deficiency is one of the most common enzymopathies worldwide, with high allele frequencies in regions including sub-Saharan Africa, the Mediterranean basin, the Middle East, and parts of Asia, shaped by historical selective pressures. Public health programs in endemic areas coordinate newborn screening, counseling by genetic services, and educational campaigns by ministries of health and international organizations. Epidemiological studies by academic consortia and global health groups assess prevalence, burden of neonatal morbidity, and implications for malaria treatment policies, especially where antimalarial drugs interact with G6PD status.
Historical descriptions of drug-induced hemolysis led to biochemical discovery and genetic characterization of the enzyme deficiency by researchers and clinicians during the 20th century, prompting development of screening and management strategies. Current research directions include population genomics projects, structure–function studies by protein chemists, development of rapid point-of-care diagnostics by biomedical engineers, and clinical trials exploring novel therapeutics and gene-editing approaches coordinated by translational research institutes. Ongoing interdisciplinary collaboration among universities, hospitals, regulatory bodies, and patient advocacy organizations aims to improve outcomes through precision medicine, surveillance, and education.
Category:Genetic disorders